poisar

Stock

Royalty Pharma plc RPRX

$61.80-0.45%

Overview

RPRX market data

Price History

RPRX price chart · 1M
O
61.72
H
62.11
L
61.55
C
61.80
Vol
81,741.00
Source
US equities market feed
Observed
Aug 26, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$61.72
Previous Close
$62.08
Day High
$62.11
Day Low
$61.55
52 Week High
$62.45
52 Week Low
$44.53
7 Day Return
+0.11%
30 Day Return
+5.70%
90 Day Return
+13.92%
1 Year Return
+36.70%
Daily Notional Volume
$5.1M
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
41.11
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
$1.37
Diluted earnings per share over the trailing twelve months.
Beta
0.42
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
3.0%
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
32.1%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$34.08 – $62.46
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $33.5B · P/B 3.44 · P/S 13.21.

Company News

10 captured
Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder DrugBenzinga · Aug 13, 2026, 5:07 PM
Royalty Pharma Announces $100M Agreement To Acquire Zealand Pharma's Rusfertide Economics, Including 1% Global Royalty; $50M At Closing, $50M On First AnniversaryBenzinga · Aug 12, 2026, 8:23 PM
JP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $62Benzinga · Aug 7, 2026, 4:46 PM
8-K filing — Royalty Pharma plc (RPRX)SEC EDGAR · Aug 5, 2026, 11:33 AM
Royalty Pharma Q2 Adj. EPS $1.32 Beats $1.28 Estimate, Sales $674.000M Miss $693.190M EstimateBenzinga · Aug 5, 2026, 11:27 AM
AstraZeneca, GameStop, Snap And Other Big Stocks Moving Lower In Monday’s Pre-Market SessionBenzinga · Aug 3, 2026, 12:01 PM
Neurimmune Sells Portion Of Its Royalty Interest In Cliramitug To Royalty Pharma For Up To $425M, Including $125M UpfrontBenzinga · Jul 22, 2026, 10:54 AM
TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $65Benzinga · Jul 13, 2026, 6:06 PM
Teva Reports Early Skin Repigmentation Data, Sets Stage For Next TrialBenzinga · Jul 7, 2026, 6:25 PM
Zymeworks Targets Long-Term Cash Generation Through Theravance AcquisitionBenzinga · Jun 29, 2026, 1:25 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock